The company reported good news from a study of its hepatitis B vaccine.
News & Analysis: VBI Vaccines
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.
Neither biotech is in the front of the pack in developing a COVID-19 vaccine.
In the race for a vaccine, a pause in progress sets you back.
The biotech will present additional data for one of its pipeline candidates later this week.
Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.
Pre-clinical results indicate that both are effective in only single doses.
Investors are fired up about an analyst's enthusiastic upgrade of the biotech stock.
The potential rewards with this biotech stock are high, but so are the risks.